Industry Lunch Symposium: HER2-positive early breast cancer:  Determining adjuvant treatment following neoadjuvant therapy
Supported by Genentech

Genetech

Friday, September 6, 2019
12:45-13:45
Hall B

HER2-positive early breast cancer:  Determining adjuvant treatment following neoadjuvant  therapy
Francis Arena, USA